Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
DAYBUE™ (trofinetide), the only FDA approved treatment for Rett syndrome.
Click here to learn more
Currently Neuren is not able to offer compassionate use for NNZ-2591.
Click here to learn more
Improving the lives of people with
neurodevelopmental disabilities
So your online presence really delivers at each step
Learn more
Improving the lives of people with
neurodevelopmental disabilities
So your online presence really delivers at each step
Learn more
Improving the lives of people with
neurodevelopmental disabilities
So your online presence really delivers at each step
Learn more
Box Section Title
Products and Pipeline
Product Development Pipeline
Products
View more
Investor Information
...
View more
Latest News
...
View more
Share Price
ASX:NEU
..
Market Cap:
20 minute delay
View more
